Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 0 5 35 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 0 5 35 versus TAYTULLA.
CYCLAFEM 0.5/35 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Terminal elimination half-life of norethindrone is 5-14 hours (mean 7.6 hours); ethinyl estradiol half-life is 7-20 hours (mean ~13 hours). Steady-state is achieved within 5-7 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal excretion accounts for approximately 50-60% of the dose (as metabolites), with 30-40% excreted in feces via biliary elimination. Unchanged drug is minimal in urine.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive